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Abstract
Essential Thrombocythcythaemia (ET) is an uncommon type of myeloproliferative  disorder,
characterised by both thrombotic and haemorrhagic diathesis. No clear guidelines exist for the pre-
and post-operative management of patients undergoing cardiac surgery in the haematological and
surgical literature. This condition has profound implications in patients undergoing cardiac surgery
with the use of cardiopulmonary bypass, where heparin is used for anti-coagulation. This dilemma
is further compounded in the setting of a young patient undergoing aortic valve replacement (AVR),
where insertion of a mechanical prosthesis would be the procedure of choice. This would require
life-long anticoagulation with warfarin which can predispose these patients to catastrophic bleeding.
Using a tissue valve will subject the patient to multiple redo operations in the patient's lifetime. We
report a young patient with ET requiring AVR and discuss the dilemmas surrounding the choice of
prosthesis in this patient.
Case report
A 22 year old gentleman was referred to our cardiotho-
racic centre for consideration for aortic valve replacement
(AVR). He was diagnosed with moderate aortic valve ste-
nosis at birth. The aortic valve was bicuspid and there was
no associated significant left ventricular hypertrophy as a
neonate. He had no other past significant medical history
except for migraine. He was asymptomatic. At the age of 5
years the peak gradient (PG) across the aortic valve was 30
mmHg on trans-thoracic echocardiogram (TTE). At fol-
low-up, 1 year before referral, there was an increase in the
PG to 50 mm Hg followed by an increase to 86 mm Hg
two weeks before referral. The patient denied any symp-
toms. At the age of 21, he was found to have an isolated
thromocytosis with a platelet count of 874 × 109/L with a
normal haemoglobin, haematocrit and white blood cell
count. His inflammatory markers were negative. The
platelet count was repeatedly above 800 × 109/L. There
was no history of bleeding or thrombocytosis and no
splenomegaly on examination. He was referred to a hae-
matologist. A bone marrow aspirate showed increased
number of megakaryocytes. The bone marrow trephine
showed classical Essential Thrombocythaemia (ET) (fig-
ure 1). Cytogenetics were normal. Blood was negative for
JAK-2 gene. In view of his age (<40 yrs), absence of hyper-
tension and diabetes, he was categorised as low risk and
started on aspirin alone. However, the planned aortic
valve surgery necessitated controlling the platelet count
over the perioperative period to reduce his risk of bleeding
or thrombosis. The options were short-term use of
hydroxycarbamide with a theoretical leukaemia and tera-
togenic risk or α-interferon. The patient elected to have α-
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interferon. Within three months the platelet count was
normal, 301 × 109/L prior to surgery. He underwent an
uncomplicated AVR with a 23 mm mechanical prosthesis
(Carbomedics Inc, Texas, USA) using a semi-continuous
technique with 2/0 prolene suture. Cardiopulmonary
bypass time was 30 minutes and the cross-clamp time was
19 minutes. One million units of trasylol was adminis-
tered in the CPB circuit and another one million in the
patient. The total bleeding in the first 24 hours was 500
mls. The post-operative recovery was uneventful without
any complications. He was anti-coagulated with intrave-
nous heparin 24 hours after surgery to maintain an acti-
vated plasma thromboplastin ratio (APTR) between 2.5–
3.0. At the same time oral aspirin and warfarin were com-
menced and once the international normalised ratio
(INR) was between 2.5–3.0, heparin was stopped, he was
discharged home on day 5 post-op. Platelets on discharge
were 369 × 109/L and Hb 110 g/L.
Discussion
The pathophysiology of ET is still uncertain after more
than 70 years of its first description. It was described by
Epstein and Goedel in 1934 [1], as a non-reactive, chronic
myeloproliferative disorder. This condition is character-
ised by sustained megakaryocyte proliferation in the bone
marrow which increases the number of circulating plate-
lets in the blood. The cause of this increase in platelet pro-
duction remains unclear, though it may be a result of
autonomous production, increased sensitivities to
cytokines (eg, interleukin-3), decreased inhibition to
platelet-inhibiting factors (eg, transforming growth factor
beta), or defects in accessory cell microenvironment [2].
Platelet survival is, however, normal. Traditionally, ET
was considered a clonal disorder that involved pluripo-
tent stem cells; however, recent studies indicate that some
patients may have polyclonal haematopoiesis [3]. Classi-
cally, ET leads to splenomegaly and follows a clinical
course complicated by haemorrhagic and/or thrombotic
episodes.
During cardiopulmonary bypass (CPB), there is activation
of platelets by thrombin (mainly), contact with non-
endothelial cells, heparin (administered during CPB), and
platelet-activating factor produced by a variety of cells
during extracorporeal perfusion and re-circulation of anti-
coagulated blood that has been exposed to a wound.
Platelets aggregate with each other and to monocytes and
neutrophils. This, along with the large procoagulant sur-
face of the circuit overwhelming natural circulating anti-
coagulants (antithrombin, protein C, protein S, tissue
factor pathway inhibitor and plasmin) producing
thrombin may lead to thrombosis within the circuit. The
factors affecting thrombin generation during CPB include
the amount and type of anticoagulant, surface area of the
blood-biomaterial interface, duration of exposure, turbu-
lence, stagnation, cavitation within the circuit, tempera-
ture and characteristics of the circuit [4]. That the wound
is the major source of thrombin generation during CPB
has encouraged development of strategies to discard
wound blood [5] or salvage red cells by centrifugation in
a cell saver. The mechanism by which thrombocytosis
produces thrombosis is not well defined. Several defects
have been described including hyperaggregation of plate-
lets and intra-platelet concentration of various chemicals.
Some reports show patients with an acquired deficiency of
antithrombin III, protein C, and protein S. Thrombosis
may be serious and life threatening. Especially, thrombo-
sis in the CPB circuit during cardiac surgery may prove to
be catastrophic resulting in interruption of extra-corporeal
circulation, vital organ malperfusion and thrombo-
embolic complications. The obvious complex interplay of
factors affecting platelet function in patients with ET
undergoing cardiac surgery with CPB has not been studied
and merits future research.
Cardiac surgery also predisposes the patient to a bleeding
tendency post-operatively. This is mainly due to fibrinol-
ysis caused by blood contact with the CPB circuit and by
blood suctioned from the operative field. Platelet dysfunc-
tion, heparin effect, haemodilution (reduced platelets)
and hypothermia (during CPB and post-operatively) also
contribute to postoperative bleeding. Circulating platelets
express GPIb and GPIIb/IIIa receptors [6], and the platelet
mass consists of a reduced number of morphologically
normal platelets, some abnormally shaped platelets, new
platelets, degranulated platelets, platelet membrane frag-
ments and microparticles [7]. Due to the above, bleeding
times increase and remain prolonged for several hours
Histology of the bone marrow trephine biopsy in our patient  showing increased number of megakaryocytes (Haematoxylin  & Eosin staining, Magnification 20×) Figure 1
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after protamine. The phenomenon of 'heparin rebound'
despite complete neutralization with protamine occurs
frequently. Heparin increases the sensitivity of platelets to
soluble agonists, inhibits binding to von Willebrand fac-
tor, and modestly increases template bleeding times.
Reports have shown that in patients with ET, there is a
decrease in von Willebrand ristocetin cofactor activity and
high molecular weight von Willebrand factor multimers
[8]. The results of the prothrombin time and activated par-
tial thromboplastin time studies are usually within refer-
ence ranges, but the bleeding time may be prolonged. In
ET, the site of bleeding is usually the gastrointestinal tract
but is mild in most cases. In view of the factors discussed
above, this could transform into serious haemorrhage in
ET patients who have undergone cardiac surgery recently.
In an experimental setting, aprotinin has been shown to
promote platelet adhesion [9] as well as decrease postop-
erative bleeding in patients undergoing cardiac surgery
with platelet dysfunction (treated with clopidogrel <5
days before surgery) [10]. It is for this reason we used
aprotinin in our patient.
A further dilemma in the setting of a young ET patient
undergoing aortic valve replacement (AVR) is what type of
prosthesis to use. Normally, a mechanical valve would
avoid the risk of structural deterioration that occurs with
tissue prostheses but would require life-long anticoagula-
tion with warfarin which can predispose ET patients to
catastrophic bleeding. Using a tissue valve or homograft
will subject the patient to multiple redo operations in the
patient's lifetime which would subject the patient to
thrombo-embolic and bleeding risks of cardiac surgery
alluded to above. In our case, detailed discussions were
carried out with the haematologist. The patient was con-
sidered a low-risk ET patient due to being young with no
previous history of bleeding, no hypertension or diabetes
a young age and good response to treatment. In consulta-
tion with the patient it was decided that life-long warfarin
would be a safe option and a mechanical valve was
inserted.
The issue of haemorrhagic diathesis would become even
more serious in the rare instance of transformation of ET
into AML [11] in patients on warfarin, in which case more
aggressive treatment (chemotherapy and bone marrow
transplantation) may be required. Stopping anti-coagula-
tion in the event of bleeding complications (mainly
bleeding gums, purpura and multiple ecchymoses) or for
therapeutic intervention (allogenic or autologous bone
marrow transplantation) may lead to valve thrombosis
and eventual mechanical valve failure. Bleeding may be
caused by thrombocytopenia, coagulopathy that results
from disseminated intravascular coagulation (DIC), or
both.
Management of ET patients undergoing cardiac surgery
under CPB should be individualized based on risk factors
for thrombo-haemorrhagic complications. Patients
undergoing surgery are at increased risk for bleeding and
thrombosis. Advice from haematologist must be sought to
help manage patients with ET and monitor therapy.
Observation may be appropriate for low-risk patients.
High risk patients include older patients (>60 years), his-
tory of thrombosis, platelet count >1500 m/ml, which is
paradoxically associated with an increased risk of GI tract
bleeding in young women, obesity, cardiovascular risk
factors and markers of hypercoagulability such as factor V
Leiden and antiphospholipid antibodies [12]. Recom-
mend lifestyle modifications (eg, weight loss for obese
patients, smoking cessation for smokers). One should
strongly consider administering cytoreductive drugs like
hydroxycarbamide, anagrelide, interferon α to reduce the
platelet count to the reference range prior to surgery [13].
In addition, low-dose aspirin may be useful in the preven-
tion microvascular occlusion and major bleeding. In an
emergency, plateletpheresis may be useful to achieve a
rapid decrease in platelet counts in the setting of acute
thrombosis and/or marked thrombocytosis. Splenectomy
performed for any reason can markedly increase the plate-
let count and the risk of both hemorrhagic and throm-
botic events.
Conclusion
The decision to choose a mechanical versus tissue prosthe-
sis in young ET patients requiring AVR is not an easy one.
Until more research reveals laboratory investigations and/
or markers which can clearly define patients more prone
either to bleeding or thrombosis, clinical strategy will
need to be tailored on the basis of clinical presentation of
ET and weighing the risks and benefits of the treatment
options available.
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